基于微流控芯片装置的临床患者循环肿瘤细胞分选及分析

摘要
图/表
参考文献(26)
相关文章 (11)

全文: PDF (844 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的分析循环肿瘤细胞（CTC）检测结果与患者临床病理特征及疗效相关性。方法选取2017年1月至2018年12月在大连大学附属中心医院的55例不同癌种的初治患者，利用前期基于微流控芯片构建的CTC检测装置，检测临床肿瘤患者外周血CTC，分析CTC检出率与患者发病年龄、性别、肿瘤分化程度、肿瘤临床分期、不同肿瘤类别及肿瘤转移情况的相关性。采用Kappa法分析CTC治疗前后数目变化与影像学疗效评价间的一致性。结果 55例恶性肿瘤患者中，CTC阳性例数为29例，检出率为52.73%，并发现检出率与肿瘤分化程度、肿瘤分期及转移相关（P ＜ 0.05），而与发病年龄、性别及癌种无关（P ＞ 0.05）。一致性分析发现，治疗前后相同患者CTC检出数目的变化情况与临床影像学检查评效结果相一致（P ＞ 0.05）。结论基于微流控芯片的CTC分选有助于协助恶性肿瘤分期、分化程度评估、转移预测及评价疗效。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	姜佳宁王琪王若雨高金琦陈雯婷王刚

关键词 ：循环肿瘤细胞, 肿瘤分化, 肿瘤分期, 肿瘤转移, 疗效评价

Abstract：Objective To analyze the relevance of the results of the circulating tumor cells (CTC) detection to the clini pathological features and curative effect of the patients. Methods A total of 55 patients with different cancer types of treated first from January 2017 to December 2018 in Affiliated Zhongshan Hospital of Dalian University were selected, the CTC detection device based on microfluidic chip was used to detect CTC in peripheral blood of clinical tumor patients. The correlation between CTC detection rate and age of onset, gender, degree of tumor differentiation, clinical stage of tumor, different tumor types and tumor metastasis of patients was analyzed. Kappa method was used to analyze the consistency between the number changes before and after CTC treatment and the evaluation of imaging efficacy. Results Among the 55 patients with malignant tumor, 29 cases were positive for CTC, and the detection rate was 52.73%. It was found that the detection rate was correlated with the degree of tumor differentiation, tumor stage and metastasis (P ＜ 0.05), but not correlated with the age of onset, gender and cancer type (P ＞ 0.05). Consistency analysis showed that, the changes of CTC detected in the same patients before and after treatment were consistent with the evaluation results of clinical imaging examination (P ＞ 0.05). Conclusion Peripheral blood CTC detection by microfluidic chip contributes to tumor staging, tumor differentiation evaluation, metastasis identification, and the curative efficacy evaluation.

Key words： Circulating tumor cells Tumor stage Tumor differentiation Tumor metastases Curative efficacy evaluation

基金资助:国家自然科学基金青年科学基金项目（81803 109）；
辽宁省博士科研启动基金计划项目（2019-BS-010）。

通讯作者: 王刚（1973.3-）男，博士，主任医师；研究方向：肺癌为主的多种恶性肿瘤的综合治疗。

作者简介: 姜佳宁（1988.7-），女，博士；研究方向：基于微流控芯片的肺癌转移的基础及临床研究。

引用本文:

姜佳宁王琪王若雨高金琦陈雯婷王刚. 基于微流控芯片装置的临床患者循环肿瘤细胞分选及分析[J]. 中国医药导报, 2022, 19(14): 88-92.
JIANG Jianing WANG Qi WANG Ruoyu GAO Jinqi CHEN Wenting WANG Gang. Isolation and analysis of circulating tumor cells in patients by a microfluidic chip device. 中国医药导报, 2022, 19(14): 88-92.

链接本文:

https://www.yiyaodaobao.com.cn/CN/ 或 https://www.yiyaodaobao.com.cn/CN/Y2022/V19/I14/88

[1] Bright CJ，Reulen RC，Winter DL，et al. Risk of subsequent primary neoplasms in survivors of adolescent and young adult cancer （Teenage and Young Adult Cancer Survivor Study）：a population-based，cohort study [J]. Lancet Oncol，2019，20（4）：531-545.
[2] Siegel RL，Miller KD，Jemal A. Cancer statistics，2016 [J]. CA Cancer J Clin，2016，66（1）：7-30.
[3] Costa C，Muinelo-Romay L，Cebey-López V，et al. Analysis of a Real-World Cohort of Metastatic Breast Cancer Patients Shows Circulating Tumor Cell Clusters （CTC-clusters） as Predictors of Patient Outcomes [J]. Cancers（Basel），2020，12（5）：1111-1129.
[4] Chen J，Ye C，Dong J，et al. Metabolic classification of circulating tumor cells as a biomarker for metastasis and prognosis in breast cancer [J]. J Transl Med，2020，18（1）：59-67.
[5] Mark D，Haeberle S，Roth G，et al. Microfluidic lab-on-a-chip platforms： requirements，characteristics and applications [J]. Chem Soc Rev，2010，39（3）：1153-1182.
[6] Jiang J，Zhao H，Shu W，et al. An integrated microfluidic device for rapid and high-sensitivity analysis of circulating tumor cells [J]. Sci Rep，2017，7：42612.
[7] Arrieta O，Aviles-Salas A，Orozco-Morales M，et al. Association between CD47 expression，clinical characteristics and prognosis in patients with advanced non-small cell lung cancer [J]. Cancer Med，2020，9（7）：2390-2402.
[8] Pei H，Li L，Han Z，et al. Recent advances in microfluidic technologies for circulating tumor cells： enrichment，single-cell analysis，and liquid biopsy for clinical applications [J]. Lab Chip，2020，20（21）：3854-3875.
[9] Zheng X，Fan L，Zhou P，et al. Detection of Circulating Tumor Cells and Circulating Tumor Microemboli in Gastric Cancer [J]. Transl Oncol，2017，10（3）：431-441.
[10] Liao CJ，Hsieh CH，Hung FC，et al. The Integration of a Three-Dimensional Spheroid Cell Culture Operation in a Circulating Tumor Cell （CTC） Isolation and Purification Process：A Preliminary Study of the Clinical Significance and Prognostic Role of the CTCs Isolated from the Blood Samples of Head and Neck Cancer Patients [J]. Cancers （Basel），2019，11（6）：783-797.
[11] Chu PY，Hsieh CH，Wu MH. The Combination of Immunomagnetic Bead-Based Cell Isolation and Optically Induced Dielectrophoresis （ODEP）-Based Microfluidic Device for the Negative Selection-Based Isolation of Circulating Tumor Cells （CTCs） [J]. Front Bioeng Biotechnol，2020，11（8）：921-935.
[12] Takagi H，Dong L，Kuczler MD，et al. Analysis of the Circulating Tumor Cell Capture Ability of a Slit Filter-Based Method in Comparison to a Selection-Free Method in Multiple Cancer Types [J]. Int J Mol Sci，2020，21（23）：9031-9046.
[13] Cheng J，Liu Y，Zhao Y，et al. Nanotechnology-Assisted Isolation and Analysis of Circulating Tumor Cells on Microfluidic Devices [J]. Micromachines（Basel），2020， 11（8）：774-800.
[14] Huang Q，Wang Y，Chen X，et al. Nanotechnology-Based Strategies for Early Cancer Diagnosis Using Circulating Tumor Cells as a Liquid Biopsy [J]. Nanotheranostics，2018，2（1）：21-41.
[15] Luo L，He Y. Magnetically driven microfluidics for isolation of circulating tumor cells [J]. Cancer Med，2020，9（12）：4207-4231.
[16] Rushton AJ，Nteliopoulos G，Shaw JA，et al. A Review of Circulating Tumour Cell Enrichment Technologies [J]. Cancers（Basel），2021，13（5）：970-1002.
[17] Jan YJ，Yoon J，Chen JF，et al. A Circulating Tumor Cell-RNA Assay for Assessment of Androgen Receptor Signaling Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate Cancer [J]. Theranostics，2019，9（10）：2812-2826.
[18] Zhao XH，Wang ZR，Chen CL，et al. Molecular detection of epithelial-mesenchymal transition markers in circulating tumor cells from pancreatic cancer patients：Potential role in clinical practice [J]. World J Gastroenterol，2019， 25（1）：138-150.
[19] Reduzzi C，Di Cosimo S，Gerratana L，et al. Circulating Tumor Cell Clusters Are Frequently Detected in Women with Early-Stage Breast Cancer [J]. Cancers（Basel），2021，13（10）：2356-2375.
[20] Yang C，Wei C，Wang S，et al. Combined Features Based on Preoperative Controlling Nutritional Status Score and Circulating Tumour Cell Status Predict Prognosis for Colorectal Cancer Patients Treated with Curative Resection [J]. Int J Biol Sci，2019，15（6）：1325-1335.
[21] Jin L，Zhao W，Zhang J，et al. Evaluation of the diagnostic value of circulating tumor cells with CytoSorter? CTC capture system in patients with breast cancer [J]. Cancer Med，2020，9（5）：1638-1647.
[22] Takeuchi H，Kitagawa Y. Circulating tumor cells in gastrointestinal cancer [J]. J Hepatobiliary Pancreat Sci，2010，17（5）：577-582.
[23] Wang Y，Liu Y，Zhang L，et al. Vimentin expression in circulating tumor cells （CTCs） associated with liver metastases predicts poor progression-free survival in patients with advanced lung cancer [J]. J Cancer Res Clin Oncol，2019，145（12）：2911-2920.
[24] Chen F，Zhong Z，Tan HY，et al. The Significance of Circulating Tumor Cells in Patients with Hepatocellular Carcinoma： Real-Time Monitoring and Moving Targets for Cancer Therapy [J]. Cancers （Basel），2020，12（7）：1734-1768.
[25] Ried K，Eng P，Sali A. Screening for Circulating Tumour Cells Allows Early Detection of Cancer and Monitoring of Treatment Effectiveness： An Observational Study [J]. Asian Pac J Cancer Prev，2017，18（8）：2275-2285.
[26] Matsushita D，Uenosono Y，Arigami T，et al. Clinical Significance of Circulating Tumor Cells in Peripheral Blood of Patients with Esophageal Squamous Cell Carcinoma [J]. Ann Surg Oncol，2015，22（11）：3674-3680.